During the 2022 Gastrointestinal Cancers Symposium, Zev A. Wainberg, MD, predicts how gastric cancer treatment will look in the near future.
Zev A. Wainberg, MD, professor of Medicine at UCLA and co-director of the UCLA GI Oncology Program, provides expert insight on how gastric treatment will evolve over the next 5 years.
0:08 |That's a good question. I think gastric cancer is going to get increasingly subdivided into smaller groups. I think we already know now, that HER2, MSS, or MSI should stay, And CPS you know, those are, I'd say validated biomarkers. We have a few more on the way hopefully with FGFR2B, and also claudin18, and hopefully others beyond that.
0:31 | So, I think, you know, what we'll expect to see over the next few years is more some dividing of the of the pie, which allows us hopefully to find better outcomes are also going to see better exploration of these drugs probably and beyond frontline settings and into earlier spaces such as adjuvant or neoadjuvant, gastric cancer. So, we do have hopefully a good plan for the next few years to develop new drugs and this, you know, terribly unmet need.
In Real-World Analyses, Apalutamide Delivers Quicker Responses in Prostate Cancer
June 15th 2024Benjamin Lowentritt, MD, discussed findings from real-world analyses looking at enzalutamide or abiraterone vs apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More
MOST Study Shows High Rates of Disease Progression in Low/Intermediate-Risk MF Over 4 Years
June 14th 2024MOST study shows high rates of disease progression in low/intermediate-risk myelofibrosis over 4 years, with the rate increasing over time. This offers valuable insight for a patient group with limited prior data.
Read More
Successes With T-DXd and the Need for Continued Research in Brain Metastasis
June 13th 2024In an interview with Targeted Oncology, Sarah Sammons, MD, discussed an analysis of the DESTINY-Breast03 trial, highlighting the need for further research on trastuzumab deruxtecan in other breast cancer subtypes and solid tumors with brain metastases.
Read More
Early Data Shows Axi-Cel’s Potential in Treating R/R Primary and Secondary CNS Lymphomas
June 13th 2024Findings from a phase 1 trial presented at ASCO showed that axicabtagene ciloleucel was safe with clinical activity seen among patients with relapsed/refractory primary and secondary central nervous system lymphoma.
Read More